Latest News Phoenix Pharmaceuticals, Inc. In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157 Delayed Pro 500mcg 60 count Palm Harbor Pharmacy The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York